ACTG1
Overview
ACTG1 encodes actin gamma 1, a cytoskeletal protein. In non-clear-cell renal cell carcinoma, ACTG1 has been identified as a fusion partner in the ACTG1-MITF gene fusion, which drives oncogenic transcription in papillary RCC.
Alterations observed in the corpus
- ACTG1-MITF fusion identified in pRCC (sample 159T); the fusion activates HIF1A, MET, and APEX1 and shows greater protein stability and transforming activity than wild-type MITF PMID:25401301
Cancer types (linked)
- PRCC: ACTG1-MITF fusion found in papillary renal cell carcinoma; classifies within the MiTF-high tumor subtype PMID:25401301
Co-occurrence and mutual exclusivity
- ACTG1-MITF fusion induces MET as a downstream target, placing ACTG1 fusions in the same pathway as MET amplification/mutation in pRCC PMID:25401301
Therapeutic relevance
- Tumors harboring ACTG1-MITF fusion (MiTF-high subtype) may be candidates for MET-targeted therapy given downstream MET activation PMID:25401301
Open questions
- Functional mechanism by which the ACTG1-MITF fusion achieves greater protein stability than wild-type MITF is not yet characterized PMID:25401301
Sources
This page was processed by entity-page-writer on 2026-05-11.